Equity - Biotechnology
Now's a bad time to buy biotech...says Pictet biotech manager
Sector specialist says major market events could prove problematic.
Funds & Fund Managers
All calculations in EUR, unless stated
| Average Manager Total Return : -7.8% (31 March 2017 - 31 March 2018) | ||||
|---|---|---|---|---|
| Total Return | ||||
| 1 of 5 |
|
-3.2% |
||
| 2 of 5 |
|
-7.3% |
||
| 3 of 5 |
|
-7.8% |
||
| 4 of 5 |
|
-9.5% |
||
| 4 of 5 |
|
-9.5% |
||
ClearBridge’s Bauman calms clients despite contrarian stance
Equity veteran defends underperformance of his US Aggressive Growth fund.
Revealed: the four most consistent thematic managers
With selectors keen to increase exposure, we take a look at the thematics managers who are proving their worth over five years.
The 10 biggest fund industry moves in September
Citywire Selector runs down the hires, exits and switches which shook the market.
Picking the next Pictet Robotics: six selectors' top thematic funds
Finding a future favourite in niche areas is a tough task. Here's how leading investors are facing up to the challenge.
The 10 biggest fund industry moves in August revealed
All the hirings and head hunting that got the industry talking this month.